[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflamation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflamation":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,60,95,120,169,200,224,251,280,310,337],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100641855","human-pilot-study-for-the-investigation-of-the-role-of-bilberry-and-olive-bioactives-on-oxidative-stress-parameters-and-inflammatory-markers-100641855",false,"NCT07659028","Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers.","A Blinded Placebo-controlled Human Pilot Study for the Investigation of the Role of Bilberry and Olive Bioactives on Oxidative Stress Parameters and Inflammatory Markers. Relevance in European Population","BIOTRANSFORM","Inclusion Criteria:\n\n* 30-50 years old,\n* BMI\\> 25 kg\u002Fm2\n* prediabetic stage\n* hsCRP\\> 2mg\u002F L\n* HbA1c 5,7-6,4%\n* Impaired fasting glucose (IFG)\n* Caucasian\n\nExclusion Criteria:\n\n* No signed informed consent\n* Supplementation or probiotic usage in the past 8 weeks\n* Chronic gastrointestinal, inflammatory or metabolic diseases\n* Alcohol misuse\n* Pregnancy or breastfeeding\n* Acute infection during the past month",true,"ALL","30 Years","50 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"NA","Numerous plant-based foods contain bioactive compounds, in particular polyphenols, which have antioxidant, anti-inflammatory, and metabolic regulatory effects. These so-called food bioactives (FB) are converted in the human organism, in particular by the gut microbiota and microsomal (liver\u002Fintestinal) metabolism, into numerous metabolites, which often represent the actual biologically active molecules. As part of the European HORIZON-MSCA Doctoral Network \"BioTransform,\" two such food models are being studied as examples: 1. Olive products (Olea europaea L.) - representative of the Mediterranean diet, rich in secoiridoids and phenylethanols (especially hydroxytyrosol and tyrosol). 2.\n\nBilberry \u002Fblueberry (Vaccinium myrtillus L.) - representative of the Central European diet, rich in anthocyanosides. Two parallel human intervention studies will be conducted, one in Graz (WP1, DC5) and one in Athens (WP1, DC3). These pilot studies will generate biological samples (blood, urine, stool) and investigate the extent to which taking these standardized dietary supplements influences glucose metabolism and markers of oxidative stress and low-grade inflammation.",[29,30,31,32],"Prediabetes","Obesity & Overweight","Inflamation","Oxidative Stress",[34,35,36,37,38,39,40,41,42,43,44,45,46],"FOOD BIOACTIVES","FOOD BIOACTIVE COMPOUNDS","OLIVE PRODUCTS","BILBERRY PRODUCTS","OLEA EUROPEA L.","BILBERRY","VACCINUM MYRTILLOUS L.","GUT MICROBIOME","MICROBIOME MAPPING","IN VITRO","IN SILICO","BIOACTIVE COMPOUNDS","METABOLISM","NOT_YET_RECRUITING","2026-06-15",{"date":50,"type":51},"2026-06-22","ACTUAL",{"date":53,"type":23},"2026-07-01",{"date":55,"type":23},"2029-10-31",{"name":57,"class":58},"National and Kapodistrian University of Athens","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":18,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":24,"phases":70,"briefSummary":71,"conditions":72,"keywords":78,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":59},"100642279","experimental-evidence-of-the-impact-of-parental-income-on-child-mental-health-and-neuroimmune-function-100642279","NCT07641244","Experimental Evidence of the Impact of Parental Income on Child Mental Health and Neuroimmune Function","Inclusion Criteria:\n\n* Child of a participant enrolled in the Every Dollar Counts intervention. Youth were between ages 5 and 14 at the start of the intervention (followed up when ages 10 to 18)\n* Biological parent who lives with the child must be part of the original income study\n* For the in-person neuroimaging subsample: family must live within a 2-hour drive of downtown Chicago\n\nExclusion Criteria:\n\n* Youth not between ages 5 and 14 at the start of the intervention\n* Parent not enrolled in the Every Dollar Counts program","10 Years","18 Years",{"count":69,"type":23},500,[26],"Growing up in a lower-income family robustly predicts worse mental health in adolescence and early adulthood. How does variability in family income \"get under the skin\" of the developing child and via what mechanisms does it increase risk for mental illness? Moreover, could supplements to family income at critical developmental periods help to prevent later youth mental illness? To address these questions, we leverage an innovative existing double blind randomized controlled trial of 3-years of substantial income supplements to parents.\n\nBy experimentally studying the impacts of these income supplements on families and subsequent youth development, we can examine causal pathways from family income to risk for mental illness via family stress and neuroimmune mechanisms in ways never done before. Moreover, by measuring the longer-term impact of 3 years of income supplements to parents on their child's neuroimmune signaling and risk for mental illness, we can examine the policy implications for child development of unconditional cash transfers to parents and identify how and for whom these supplements help. We will test these basic and translational questions in a sample of 1,200 youth with lower-income parents randomly assigned to receive either a substantial monthly income supplement or a minimal monthly supplement for 3 years, starting when youth were between age 5 - 14 years old. We will follow up with youth and their parent 1 - 2 and 3 - 4 years after the intervention and examine whether income supplements predict better youth mental health during adolescence, as well as whether factors like child age and neighborhood quality modulate intervention effects. Additionally, we explore family stress mechanisms through which the intervention may impact child mental health. Finally, we will measure peripheral inflammation (inflammatory biomarkers and classical monocytes) and use MRI to assess threat, reward, and regulatory neural activity and connectivity among 500 of these youth. Our central hypothesis is that income supplements will decrease family and youth stress and improve parenting, which will improve neuroimmune signaling and decrease risk for psychopathology. Moreover, these effects will remain years after termination of the transfers and be strongest among families who received the intervention earlier in the child's life. This research will provide timely, relevant public health knowledge that will help policy makers understand the longer-term brain, immune, and mental health impacts of cash transfers to parents, while also advancing the science of the sociocontextual and neuroimmune pathways through which variability in family income impacts risk for psychopathology.",[73,74,75,76,31,77],"Psychopathology","Child Mental Health","Anxiety Disorders","Mental Disorders","Poverty",[79,80,81,82,83,77,74,73,84],"Depression","Anxiety","Internalizing Disorders","Externalizing Disorders","Inflammation","Stress","RECRUITING","2026-06-08",{"date":88,"type":51},"2026-06-11",{"date":90,"type":51},"2026-04-04",{"date":92,"type":23},"2029-08-31",{"name":94,"class":58},"Northwestern University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":18,"minAge":67,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":59},"100639070","fdg-petmri-imaging-of-patellofemoral-joint-osteoarthritis-100639070","NCT07625150","FDG PET\u002FMRI Imaging of Patellofemoral Joint Osteoarthritis","Understanding Painful Inflammation in Patellofemoral Joint OA Using [18F] FDG","FDG-PFJOA","Inclusion Criteria:\n\n* Adult with the capacity to give informed consent\n* Ability to perform 25 single-leg squats\n* No traumatic knee injuries\u002Fsurgeries since last visit for the parent study (IRB #21-34763)\n* No investigational drugs since last visit for the parent study (IRB #21-34763)\n* No contraindications to MRI or PET tracer since last visit for the parent study (IRB #21-34763)\n* Not taking steroid injections\n* Not pregnant\n* Additional inclusion criteria for healthy volunteers: Minimal pain (VAS=0-1) during a series of 25 single-leg squats on one or both legs\n\nExclusion Criteria:\n\n* Inability to consent for themselves\n* Inability to perform 25 single-leg squats with the study leg\n* New traumatic knee injuries\u002Fsurgeries since last visit for the parent study (IRB #21-34763)\n* Taking investigational drugs since last visit for the parent study (IRB #21-34763)\n* New contraindications to MRI or PET tracer since last visit for the parent study (IRB #21-34763)\n* Taking steroid injections\n* Pregnant\n* Diabetic\n* Additional exclusion criteria for healthy volunteers: VAS of 2 or greater during a series of 25 single-leg squats on both legs",{"count":104,"type":23},50,"OBSERVATIONAL","This project aims to develop an \\[18F\\] fluorodeoxyglucose (FDG) positron emission tomography (PET) \u002F magnetic resonance imaging (MRI) method to locate the painful inflammation in PFJ OA associated with joint loading. \\[18F\\] FDG PET\u002FMRI is an emerging pain imaging approach with enhanced sensitivity to painful hypermetabolic inflammation through evaluation of intracellular glucose utilization rate via (\\[18F\\]FDG PET) and fine anatomy details (MRI). The investigative group has shown its promise in revealing previously unidentified or unspecified pain generators in various musculoskeletal pain conditions. The investigators have also demonstrated the feasibility of visualizing the structural changes between unloaded and loaded knee joints with MRI, which can be easily adopted in the current PET\u002FMRI setting. The main challenge in the proposed \\[18F\\]FDG PET\u002FMRI approach is to differentiate the normal uptake of FDG for metabolic changes by weight-bearing from abnormal changes indicating eventual pain aggravation by weight-bearing and knee-flexion. The investigators have garnered the following two aims to validate the proposed method by comparing unloaded and loaded knee imaging results between PFJ OA pain patients and asymptomatic, matched controls.",[108,109,110,31],"Patellofemoral Osteoarthritis","Knee Osteoarthritis","Knee Pain","2026-06-01",{"date":113,"type":51},"2026-06-04",{"date":115,"type":51},"2025-02-19",{"date":117,"type":23},"2028-02",{"name":119,"class":58},"University of California, San Francisco",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":17,"sex":127,"minAge":128,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":24,"phases":132,"briefSummary":133,"conditions":134,"keywords":141,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":59},"100639704","algal-lutein-against-decline-of-intellectual-nimbleness-100639704","NCT07600567","Algal Lutein Against Decline of Intellectual Nimbleness","ALADIN","Inclusion Criteria:\n\n* Females\n* Age 48-60 years\n* Postmenopausal status (natural menopause, up to 5 years after menopause)\n* waist circumference ≥ 88 cm\n\nExclusion Criteria:\n\n* Diagnosis of dementia or cognitive impairment\n* Use of hormone replacement therapy within the last 6 months\n* Advanced age-related macular degeneration\n* History of major untreated neurological or psychiatric disorders (including depression, Parkinson's disease, Alzheimer's disease, psychiatric disorders, stroke within the last 3 months)\n* Presence of chronic diseases, including: diabetes mellitus (type 1 or 2), lipid disorders, cardiovascular diseases, thyroid diseases, anemia, liver diseases, gastrointestinal disorders, or cancer within the last 5 years\n* Use of anti-inflammatory medications or medications targeting lipid or carbohydrate metabolism within the last 3 months\n* Alcohol consumption \\> 100 g per week\n* Use of lutein-containing supplements","FEMALE","48 Years","60 Years",{"count":131,"type":23},300,[26],"Lutein is a xanthophyll pigment found in photosynthesizing organisms. Its beneficial effects on health, including brain function and visual performance, have been recognized for many years. However, to date, only a limited number of well-designed human intervention studies have been published regarding the effects of incorporating lutein into the daily diet (as humans are unable to synthesize lutein endogenously). Unfortunately, within the Western dietary pattern, the average daily intake of lutein is approximately 1.7 mg, whereas achieving health benefits- such as reducing the risk of age-related macular degeneration and cataract, as well as neurodegenerative diseases- requires an intake of 6 to 14 mg per day.\n\nIn light of the above, it is therefore justified to enrich the daily diet with products that are sources of lutein. Unfortunately, the consumption of dark green vegetables- the richest dietary source of lutein-remains insufficient. Lutein preparations currently available on the market are extracted from marigold or calendula flowers. However, lutein production from these raw materials requires greater water consumption and land use, which is not aligned with the principles of sustainable development. An alternative approach involves the production of lutein preparations from microalgae (from species approved as food by the European Food Safety Authority, EFSA), as the rate of lutein production from microalgae is three to six times higher than that from marigold flowers.\n\nTaking the above into account, the primary objective of this project is to evaluate the dose-response relationship in establishing the anti-aging mechanism of action of lutein derived from microalgae.\n\nAs part of the project, a six-month randomized, placebo-controlled trial is planned. The study will include 300 polish women (aged 48-60 years), after natural menopause, with visceral obesity (waist circumference ≥ 88 cm). In order to enable the inclusion of such a large study population, the research team will conduct intensified recruitment efforts for several months prior to the initiation of the dietary intervention.\n\nParticipants who meet the inclusion criteria will be randomly assigned to one of three groups: lutein supplementation at a dose of 6 mg (n = 100), lutein supplementation at a dose of 14 mg (n = 100), or placebo (n = 100). The volunteers will be instructed to take the prescribed preparation daily for 180 days. All preparations will be identical in appearance, taste, and smell.\n\nAll volunteers expressing willingness to participate in the experiment will be asked to provide written informed consent prior to enrollment in the study.\n\nThe study will be conducted in accordance with the previously calculated sample size (n = 300 postmenopausal women with visceral obesity). In order to obtain a homogeneous study population, appropriate inclusion and exclusion criteria will be applied.\n\nConducting the research in such a large and homogeneous group will enable the generation of high-quality scientific evidence identifying the dose of microalgae-derived lutein that allows for the determination of its anti-aging mechanism of action. It will also be possible to elucidate the potential role of short-chain fatty acids (SCFAs) in feces in this process, which may represent a significant novelty in this field of research.\n\nThe study will contribute to the development of new knowledge regarding the anti-aging properties of lutein derived from microalgae in populations vulnerable to cognitive impairment (postmenopausal women). However, microalgae-derived lutein may be used as a dietary supplement not only in the studied group but also in the general population.\n\nThe specific objectives are as follows:\n\n* To assess the effect of lutein derived from microalgae (at doses of 6 mg and 14 mg) on the concentration of brain-derived neurotrophic factor (BDNF), inflammatory markers, cardiometabolic parameters, fecal short-chain fatty acid (SCFA) concentrations, and cognitive function in postmenopausal women with visceral obesity.\n* To evaluate adherence to lutein supplementation recommendations (by assessing macular pigment optical density).\n* To determine whether supplementation with microalgal lutein increases fecal SCFA concentrations and whether SCFAs may act as mediators in improving inflammatory markers and cognitive function in postmenopausal women with visceral obesity.\n* To determine whether supplementation with microalgal lutein (at doses of 6 mg and 14 mg) affects changes in selected gut bacterial populations and β-glucuronidase enzymatic activity in postmenopausal women with visceral obesity.\n* To analyse the association between polymorphisms in genes related to lutein metabolism and transport in the body and the effectiveness of supplementation with this compound.\n* To identify dietary behaviour patterns associated with high exposure to bisphenol A (BPA) and the presence of inflammation in postmenopausal women with visceral obesity.",[135,136,30,137,31,138,139,140],"Menopausal Syndrome","Cognitive Decline","Menopause","Gut Dysbiosis","Bisphenol A","Cardio Vascular Disease",[142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159],"menopausal syndrome","cognitive decline","obesity","menopause","inflammation","dysbiosis","bisphenol A","gut microbiota","BNDF","intellectual nimbleness","beta-glucuronidase","lutein","supplementation","micro-algae","gene polimorfism","eye vision","chlorella","sustainable development","2026-05-13",{"date":162,"type":51},"2026-05-20",{"date":164,"type":23},"2026-05-01",{"date":166,"type":23},"2027-04-30",{"name":168,"class":58},"Poznan University of Life Sciences",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":127,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":24,"phases":179,"briefSummary":180,"conditions":181,"keywords":186,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":196,"leadSponsor":198,"locationsCount":4},"100637766","effects-of-moderate-intensity-interval-aerobic-exercise-miiae-on-inflammatory-immune-metabolic-physical-fitness-and-quality-of-life-parameters-in-breast-cancer-patients-undergoing-radiotherapy-100637766","NCT07583719","Effects of Moderate-intensity Interval Aerobic Exercise (MIIAE) on Inflammatory, Immune, Metabolic, Physical Fitness, and Quality of Life Parameters in Breast Cancer Patients Undergoing Radiotherapy.","Inclusion Criteria:\n\n* Women aged between 20 and 65 years.\n* Clinical diagnosis of breast cancer (Stage I-III).\n* Patients who have undergone lumpectomy or mastectomy.\n* Scheduled to start radiotherapy treatment.\n* Sedentary lifestyle according to international physical activity guidelines.\n* Ability to understand and follow instructions.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Presence of infectious disease.\n* Cardiovascular or respiratory disease.\n* Metastatic disease.\n* Uncontrolled diabetes mellitus.\n* Neuropathy.\n* Physically active individuals meeting WHO physical activity recommendations.\n* Participation in an exercise intervention program within the last 3 months.\n* Any condition that, in the opinion of the research team, may compromise safety or participation.","20 Years","65 Years",{"count":178,"type":23},40,[26],"Breast cancer and its treatment with radiotherapy may be associated with systemic inflammatory, hematological, cardiac, body composition, functional and quality-of-life alterations. Exercise has emerged as a non-pharmacological strategy with potential benefits during oncological treatment; however, further evidence is needed regarding the effects of supervised moderate-intensity interval aerobic exercise during radiotherapy.\n\nThis randomized controlled trial aims to evaluate the effects of a supervised moderate-intensity interval aerobic exercise programme on systemic inflammatory and immune-derived hematological indices, cardiac biomarkers, body composition, muscle strength, lower-limb power, sleep quality and breast cancer-specific quality of life in women with breast cancer undergoing radiotherapy.\n\nParticipants will be allocated to either an experimental group performing supervised moderate-intensity interval aerobic exercise during radiotherapy or to a control group receiving usual care without structured exercise during the study period. Outcomes will be assessed at baseline and after completion of the intervention period.",[182,31,183,184,185],"Radiotherapy","Immune System","Physical Fitness","Breast Cancer",[187,83,188,189,190,185,191,192],"Interval Training","Body Composition","Quality of Life","Immune function","Sleep","oncology rehabilitation","2026-05-06",{"date":160,"type":51},{"date":111,"type":23},{"date":197,"type":23},"2026-12-31",{"name":199,"class":58},"Universidad Francisco de Vitoria",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":17,"sex":18,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":24,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":59},"100626711","impact-of-a-cricket-and-black-soldier-fly-larvae-fortified-cracker-on-the-gut-microbiome-and-iron-status-in-malagasy-schoolchildren-100626711","NCT07439185","Impact of a Cricket and Black Soldier Fly Larvae-Fortified Cracker on the Gut Microbiome and Iron Status in Malagasy Schoolchildren","Inclusion criteria for children\n\n* Child (male, female, intersex, non-binary), aged 9 to 13 years old who attends one of the selected schools\n* Caregiver or legal guardian is willing to provide informed consent\n* Child is willing to provide informed assent\n\nExclusion criteria for children\n\n* Child age is outside the preferred age range (9 to 13 years)\n* Not enrolled in the participating schools\n* Unable or unwilling to comply with the study requirements\n* Illness requiring medical treatment, malaria, severe anemia (hemoglobin (Hb) concentration below 8.0 g\u002FdL as indicated by HemoCue 201+ system), severe acute malnutrition, fever, diarrhea, etc.\n* Covid-exposure or symptoms: loss of smell or taste\n* History of food allergies or adverse reactions to any edible insects\n* Chronic severe medical condition or congenital anomalies requiring frequent medical attention or interfering with dietary consumption\n* Caregiver does not give consent, or child does not assent\n\nInclusion criteria for parents • Willing to participate in completing surveys about demographics and household dynamics (assets, housing structure, etc.)\n\nExclusion criteria for parents\n\n• Caregiver does not consent to participate","9 Years","13 Years",{"count":209,"type":23},650,[26],"The purpose of this study is to determine the health impacts of consistent consumption of insect-fortified crackers among school-aged children in Madagascar.\n\nSpecifically, in this RCT, the investigators will assess whether the insect-fortified crackers can improve the health status of Malagasy school children. The investigators' objectives are to: (1) Assess changes in gut microbiome composition that occur after 6 and 14 weeks of cracker consumption through 16S rRNA sequencing. (2) Assess changes in intestinal and systemic inflammation after 6 and 14 weeks of cracker consumption through quantification of fecal calprotectin, lactoferrin, myeloperoxidase (MPO), and alpha-1-antitrypsin (AAT) and circulating pro-inflammatory cytokines. (3) Assess changes in iron status after 14 weeks of cracker consumption through quantification of hemoglobin (Hb), inflammation-adjusted serum ferritin, and soluble transferrin receptor (sTfR).",[213,31,214],"Gut -Microbiota","Iron Absorption","2026-02-23",{"date":217,"type":51},"2026-02-27",{"date":219,"type":23},"2026-02",{"date":221,"type":23},"2026-06",{"name":223,"class":58},"Cornell University",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":18,"minAge":67,"maxAge":176,"enrollmentInfo":231,"targetDuration":4,"studyType":24,"phases":233,"briefSummary":234,"conditions":235,"keywords":238,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":4},"100617904","evaluation-of-irisin-levels-in-adult-forearm-fracture-surgery-under-infraclavicular-block-and-general-anesthesia-100617904","NCT07324681","Evaluation of Irisin Levels in Adult Forearm Fracture Surgery Under Infraclavicular Block and General Anesthesia","Evaluation of Irisin Levels in Adult Patients With Forearm Fractures Undergoing Surgery With Infraclavicular Block and General Anesthesia","Inclusion Criteria:\n\n* Adults aged 18 to 65 years\n\nScheduled for elective forearm fracture surgery\n\nPlanned to receive either general anesthesia or infraclavicular brachial plexus block\n\nAmerican Society of Anesthesiologists (ASA) physical status I-III\n\nAble to provide written and verbal informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>65 years\n\nEmergency surgery\n\nRefusal or inability to provide informed consent\n\nASA physical status IV or V\n\nKnown bone diseases or metabolic bone disorders\n\nMultiple trauma or associated organ injury\n\nInability to mobilize\n\nMorbid obesity (BMI \\>40 kg\u002Fm²)\n\nRenal failure\n\nHepatic failure\n\nNeurological deficits or sequelae\n\nContraindication or allergy to any anesthetic agents used in the study",{"count":232,"type":23},90,[26],"This randomized prospective study evaluates the effect of general anesthesia versus infraclavicular nerve block on perioperative serum irisin levels in adults undergoing forearm fracture surgery. Irisin levels will be measured preoperatively, at 30 minutes postoperatively, and at 24 hours postoperatively. The association between irisin changes and fracture healing will be explored as a secondary outcome.",[31,236,237],"Healing","Angiogenesis",[239,240,241],"irisin","infraclavicular block","forearm fracture","2026-01-07",{"date":244,"type":51},"2026-01-09",{"date":246,"type":23},"2026-01-25",{"date":248,"type":23},"2026-05-05",{"name":250,"class":58},"Ankara City Hospital Bilkent",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":18,"minAge":67,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":24,"phases":261,"briefSummary":263,"conditions":264,"keywords":268,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":59},"100615461","phase-4-effect-of-empagliflozin-on-inflammation-100615461","NCT07292909","Effect of Empagliflozin on Inflammation","Randomized Trial to Evaluate the Anti-inflammatory Effects of Empagliflozin Following PCI","EMPANTINFLAM","Inclusion Criteria:\n\n* • Patients with stable CAD who are electively scheduled for PCI on a de novo lesion in a native coronary artery\n\nExclusion Criteria:\n\n* • Patients who have been taking an SGLT-2 inhibitor during the last month\n\n  * Patients who are receiving any anti-inflammatory medication: immunosuppressor, steroids, NSAID…\n  * Patients who have underlying inflammatory conditions such as rheumatic arthritis, infection, active malignancy\n  * Patients with an acute coronary syndrome within the last month\n  * Intervention on a restenotic lesion or lesion in a saphenous vein graft\n  * Creatinine clearance less than 30 mL\u002Fmin\n  * Patients who are treated with devices other than balloons and stents (lithotripsy, rotational atherectomy…)",{"count":260,"type":23},100,[262],"PHASE4","Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure. The exact mechanism of this effect is currently not clearly understood.\n\nHe hypothesize that empagliflozin has other properties than glucose lowering, that can explain its efficacy. One of these properties, is an anti-inflammatory effect.\n\nTo document this, we are using a model of inflammation following percutaneous coronary scenting. We know that patients who get a stent will develop inflammation following stenting. This is documenting by a higher level of C-Reactive Protein 24 hours after the procedure.\n\nPatients who will participate in the study, will receive empagliflozin or a placebo tablet for 3 days prior to the revascularisation procedure. CRP and other inflammatory markers will be measured before intervention and 24 hours later. The goal is to demonstrate a lower rise in CRP following intervention in patients treated with empagliflozin vs. those who have received a placebo.",[265,31,266,267],"CAD - Coronary Artery Disease","PCI","SGLT 2 Inhibitors",[269,146,270],"CAD","SGLT2 inhibitors","2025-12-06",{"date":273,"type":51},"2025-12-18",{"date":275,"type":51},"2025-09-01",{"date":277,"type":23},"2027-09-30",{"name":279,"class":58},"Hotel Dieu de France Hospital",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":17,"sex":18,"minAge":67,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":24,"phases":290,"briefSummary":291,"conditions":292,"keywords":295,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":59},"100614757","a-mindfulness-based-intervention-to-reduce-stress-through-the-cultivation-of-loving-kindness-compassion-joy-and-equanimity-in-healthcare-professionals-100614757","NCT07283744","A Mindfulness-Based Intervention to Reduce Stress Through the Cultivation of Loving-Kindness, Compassion, Joy, and Equanimity in Healthcare Professionals","Project FIERCE - Fostering Internal and External Respect, Compassion, and Equanimity: A Mindfulness-Based Intervention to Reduce Stress Through the Cultivation of Loving-Kindness, Compassion, Joy, and Equanimity in Healthcare Professionals","FIERCE","Inclusion Criteria: 1) full-time physician (M.D. or D.O.), 2) at least 18 years of age, 3) able to attend the six-week intervention, 4) fluent in English, and 5) access to the internet and email.\n\nExclusion Criteria. 1) having a current and consistent meditation practice (i.e., engaging in a formal meditation practice at least three days per week for five minutes each day), 2) previous participation in a Four Immeasurable course (e.g., attending a Brahmaviharas meditation retreat), 3) absence of at least mild levels of perceived stress as determined by a score less than five on the four-item Perceived Stress Scale (PSS-4; 92), 4) regular tobacco use (given its impact on immune function; 90), and 5) failure to agree to the informed consent. The presence or absence of perceived stress will be assessed using the PSS-4 during the initial phone screening.",{"count":289,"type":23},80,[26],"Nearly 50% of the adult workforce experience adverse psychological symptoms (e.g., stress, depression, burnout, etc.) stemming from workplace stressors, with healthcare workers experiencing rates as high as 80%. Some common complaints and downstream consequences of working in high-stress healthcare occupations are elevated levels of perceived stress, depression, and burnout. These conditions have been associated with unfavorable occupational (e.g., increased medical errors), patient (e.g., increased mortality rates), and provider-related outcomes (e.g., increased rates of cardiovascular disease), imposing a heavy burden on an already stretched system. Given the impact of perceived stress, depression, and burnout on employee and patient health, a clear need exists to develop effective interventions to reduce distress and promote well-being among healthcare professionals. In particular, interventions that target processes particularly vulnerable to provider stress (e.g., compassion) are needed.\n\nThe present study will evaluate the feasibility and efficacy of a mindfulness-based intervention inspired by the Buddhist Four Immeasurables practice on reducing perceived stress (primary outcome), depressive symptoms, burnout, and biological markers of inflammation, and enhancing psychological well-being and sleep quality (secondary outcomes) in 80 healthcare workers. Additionally, we will investigate several mediators (compassion, positive emotions, equanimity, and mindfulness) of intervention effects. Participants will be healthcare employees of UCLA Health. They will be enrolled in a six-week, two-arm randomized controlled trial. Participants will complete self-report questionnaires at baseline, mid-course, and post-intervention to assess study outcomes and mediators. We aim to advance the study of interventions that reduce distress and promote well-being using practices that cultivate kind feelings toward oneself and others.",[293,31,294],"Stress (Psychology)","Psychosocial Functioning",[296,297,298,299,300],"mindfulness","compassion","loving-kindness","healthcare professional","stress","2025-12-04",{"date":303,"type":51},"2025-12-16",{"date":305,"type":51},"2025-10-10",{"date":307,"type":23},"2027-01",{"name":309,"class":58},"University of California, Los Angeles",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":18,"minAge":67,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":24,"phases":318,"briefSummary":319,"conditions":320,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":335,"locationsCount":59},"100599814","efficacy-and-safety-of-resveratrol-in-patients-with-rheumatoid-arthritis-100599814","NCT07089381","Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.","Inclusion Criteria:\n\n* Adult patients \\> 18 years old\n* Established diagnosis of RA according to American College of Rheumatology\u002FEuropean league Against Rheumatism (ACR\u002FEULAR) 2010 criteria (Aletaha et al., 2010), presented with moderate to high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n* Patients receiving stable regimen of one or more csDMARDs for at least the past 3 months.\n* RA Patients with Moderate or high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n\nExclusion Criteria:\n\n* Patients receiving biologic DMARDs therapy for RA\n* Patients taking any other anti-inflammatory drugs\n* Patients taking any other antioxidants\n* Pregnant and lactating women\n* Other rheumatological, inflammatory diseases or malignancies\n* Smokers\n* Thyroid illnesses\n* Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin)",{"count":317,"type":23},118,[26],"The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis.\n\nObjectives :\n\n1. To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring:\n\n   * Serum Sirtuin 1(SIRT1)\n   * Serum Myeloperoxidase (MPO)\n   * Serum C-reactive protein (CRP)\n2. To investigate the effects of Resveratrol on disease activity by measuring the disease activity (DAS28 score).\n3. To investigate the effect of Resveratrol on improving the quality of life using the Health Assessment Questionnaire Disability index (HAQ-DI).\n4. To assess any adverse effects related to Resveratrol.\n\nPatients:\n\nEligible patients (no=118) will be randomly assigned in a 1:1 ratio to one of two groups:\n\n1. Control group: 59 patients will receive the standard treatment for management of RA for 3 months.\n2. Resveratrol group: 59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix Egypt) (given as one 1000 mg tablets once daily) for 3 months.",[321,322,31,323,324,325,326,327,328],"Rheumatic Arthritis","Rheumatoid Arthritis (RA) Prevention","Antioxidant","Anti Oxidative Stress","Anti Aging","C Reactive Protein","Methotrexate","Quality of Life Outcomes","2025-07-21",{"date":331,"type":51},"2025-07-28",{"date":333,"type":23},"2025-08-01",{"date":111,"type":23},{"name":336,"class":58},"Ain Shams University",{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":18,"minAge":343,"maxAge":344,"enrollmentInfo":345,"targetDuration":4,"studyType":24,"phases":346,"briefSummary":347,"conditions":348,"keywords":352,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":59},"100589794","therapeutic-strategies-for-type-2-diabetes-based-on-lifestyle-changes-plant-based-diet-and-physical-exercise-100589794","NCT06959043","Therapeutic Strategies for Type 2 Diabetes Based on Lifestyle Changes: Plant-based Diet and Physical Exercise","Inclusion Criteria:\n\n* Have a medical diagnosis of type 2 diabetes for a maximum of 5 years.\n* Be omnivorous; Have a Body Mass Index (BMI) ≥ 25 kg\u002Fm2 and \\\u003C 40 kg\u002Fm2;\n* Be between the ages of 45 and 70, both genders.\n* Women should be in the postmenopausal stage;\n* Use no more than three hypoglycemic medications in total;\n* Have the availability for a four-week consecutive hospitalization at CSVN.\n\nExclusion Criteria:\n\n* Be using insulin, anti-obesity medications, antibiotics, and\u002For probiotic supplements in the 2 months preceding data collection;\n* Use of alcohol or tobacco;\n* Have limited mobility and a previous diagnosis of cardiopulmonary diseases;\n* Report current or previous (within the past two months) diarrhea during screening;\n* Have liver or kidney failure and uncontrolled endocrine disorders (hypothyroidism, hypogonadism, and adrenal insufficiency);\n* Have eating disorders or have undergone bariatric surgery.","45 Years","70 Years",{"count":22,"type":23},[26],"The study evaluates the impact of a strict vegetarian diet combined with regular physical exercise and the use of probiotics on metabolic, inflammatory, and epigenetic parameters in patients with type 2 diabetes. It aims to determine the influence of these interventions on gut microbiota, glycemic control, body composition, insulin resistance, and quality of life.",[349,350,31,351],"Type 2 Diabetes Mellitus (T2DM)","Insulin Resistance","Gut Microbiomes",[353,350,31,354,355,356,357,358],"Type 2 Diabetes Mellitus","Metabolic Syndrome","Physical Exercise","Gut Microbiome","Plant-based Diet","Lifestyle Interventions","2025-05-13",{"date":361,"type":51},"2025-05-18",{"date":363,"type":51},"2022-11-22",{"date":365,"type":23},"2026-12",{"name":367,"class":58},"Maria Elizabeth Rossi da Silva"]